Difference between revisions of "Carcinoma of unknown primary"
Warner-admin (talk | contribs) m (Text replacement - "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy" to "!style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Comparative Efficacy") |
Warner-admin (talk | contribs) m (Text replacement - "Comparative Efficacy" to "Comparative Efficacy") |
||
Line 134: | Line 134: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.ejcancer.com/article/S0959-8049(12)00018-4/abstract Gross-Goupil et al. 2012 (GEFCAPI 02)] | |[https://www.ejcancer.com/article/S0959-8049(12)00018-4/abstract Gross-Goupil et al. 2012 (GEFCAPI 02)] | ||
Line 192: | Line 192: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://jco.ascopubs.org/content/21/18/3479.long Culine et al. 2003 (GEFCAPI 01)] | |[http://jco.ascopubs.org/content/21/18/3479.long Culine et al. 2003 (GEFCAPI 01)] | ||
Line 226: | Line 226: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://jco.ascopubs.org/content/21/18/3479.long Culine et al. 2003 (GEFCAPI 01)] | |[http://jco.ascopubs.org/content/21/18/3479.long Culine et al. 2003 (GEFCAPI 01)] | ||
Line 333: | Line 333: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://journals.lww.com/journalppo/pages/articleviewer.aspx?year=2010&issue=02000&article=00013&type=abstract Hainsworth et al. 2010] | |[http://journals.lww.com/journalppo/pages/articleviewer.aspx?year=2010&issue=02000&article=00013&type=abstract Hainsworth et al. 2010] | ||
Line 361: | Line 361: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
− | !style="width: 25%"|[[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2820001215%2989:12%3C2655::AID-CNCR19%3E3.0.CO;2-9/full Greco et al. 2000a] | |[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2820001215%2989:12%3C2655::AID-CNCR19%3E3.0.CO;2-9/full Greco et al. 2000a] |
Revision as of 18:59, 13 June 2019
Adenocarcinoma of unknown primary may also be referred to as carcinoma of unknown primary site, cancer/carcinoma of unknown primary (CUP), occult primary, or unknown primary carcinoma.
15 regimens on this page
16 variants on this page
|
Guidelines
ESMO
- 2015: Fizazi et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
NCCN
All lines of therapy
BEP
back to top |
BEP: Bleomycin, Etoposide, Platinol (Cisplatin)
PEB: Platinol (Cisplatin), Etoposide, Bleomycin
Regimen
Study | Evidence |
---|---|
Hainsworth et al 1992 | Phase II |
Chemotherapy
- Bleomycin (Blenoxane) 30 units IV once per day on days 1, 8, 15
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 5
- Cisplatin (Platinol) 20 mg/m2 IV once per day on days 1 to 5
21-day cycles
References
- Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992 Jun;10(6):912-22. link to original article contains verified protocol PubMed
Carboplatin & Docetaxel
back to top |
Variant #1
Study | Evidence |
---|---|
Pentheroudakis et al. 2008 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given second
- Docetaxel (Taxotere) 75 mg/m2 IV over 30 minutes once on day 1, given first
Supportive medications
- Dexamethasone (Decadron) 8 mg PO twice per day the day before chemotherapy
- Dexamethasone (Decadron) 16 mg IV once, prior to chemotherapy, on the day of chemotherapy
- Ondansetron (Zofran) 8 mg IV once, prior to chemotherapy
- Ranitidine (Zantac) 100 mg IV once, prior to chemotherapy
- Dimethindene maleate (Fenestil) 0.1 mg/kg (route unclear) prior to chemotherapy
21-day cycle for up to 8 cycles
Variant #2
Study | Evidence |
---|---|
Greco et al. 2000 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV over 20 minutes once on day 1, given second
- Docetaxel (Taxotere) 65 mg/m2 IV over 60 minutes once on day 1, given first
Supportive medications
- Dexamethasone (Decadron) 8 mg PO twice per day the day before, the day of, and day after chemotherapy
- Ondansetron (Zofran) 32 mg IV or Granisetron 10 mcg/kg IV 15 minutes prior to chemotherapy
21-day cycle for 4 to 8 cycles
References
- Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000 Feb;11(2):211 to 5. link to original article contains verified protocol PubMed
- Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N; Hellenic Cooperative Oncology Group. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol. 2008;47(6):1148-55. link to original article contains verified protocol PubMed
Carboplatin & Paclitaxel
back to top |
Regimen
Study | Evidence |
---|---|
Briasoulis et al. 2000 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV over 30 minutes once on day 1, given first
- Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours once on day 1, given second
Supportive medications
- Methylprednisolone (Solumedrol) 32 mg PO 24 and 12 hours before paclitaxel, and 10 minutes before carboplatin
- Dexamethasone (Decadron) 16 mg IV over 10 minutes prior to chemotherapy
- Diphenhydramine (Benadryl) 50 mg IV or dimethindene maleate 0.1 mg/kg IV over 10 minutes prior to chemotherapy
- Ranitidine (Zantac) 100 mg IV over 10 minutes prior to chemotherapy
- Ondansetron (Zofran) 8 mg IV after the above premedications
- Suggested: Filgrastim (Neupogen) 300 mcg SC once per day on days 5 to 12
21-day cycle for 6 to 8 cycles
References
- Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000 Sep;18(17):3101-7. link to original article contains verified protocol PubMed
Cisplatin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Gross-Goupil et al. 2012 (GEFCAPI 02) | Randomized Phase II (C) | Cisplatin & Gemcitabine | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
21-day cycles
References
- GEFCAPI 02: Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012 Mar;48(5):721-7. Epub 2012 Feb 6. link to original article contains verified protocol PubMed
Cisplatin & Docetaxel
back to top |
Regimen
Study | Evidence |
---|---|
Greco et al. 2000 | Phase II |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV over 60 minutes once on day 1
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1
Supportive medications
- Dexamethasone (Decadron) 8 mg PO twice per day the day before, the day of, and day after chemotherapy
- Suggested: Dexamethasone (Decadron) 20 mg IV 15 minutes prior to Cisplatin (Platinol)
- 2 liters of normal saline with chemotherapy
- Ondansetron (Zofran) 32 mg IV or Granisetron 10 mcg/kg IV 15 minutes prior to Cisplatin (Platinol)
- Ondansetron (Zofran) 8 mg PO three times per day on days 2 to 6
21-day cycle for up to 8 cycles
References
- Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000 Feb;11(2):211 to 5. link to original article contains verified protocol PubMed
Cisplatin & Gemcitabine
back to top |
GC: Gemcitabine & Cisplatin
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Culine et al. 2003 (GEFCAPI 01) | Randomized Phase II (E) | Cisplatin & Irinotecan | Not reported |
Gross-Goupil et al. 2012 (GEFCAPI 02) | Randomized Phase II (E) | Cisplatin | Seems not superior |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
- Gemcitabine (Gemzar) 1250 mg/m2 IV once per day on days 1 & 8
21-day cycles
References
- GEFCAPI 01: Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003 Sep 15;21(18):3479-82. link to original article contains verified protocol PubMed content property of HemOnc.org
- GEFCAPI 02: Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012 Mar;48(5):721-7. Epub 2012 Feb 6. link to original article contains verified protocol PubMed
Cisplatin & Irinotecan
back to top |
IC: Irinotecan & Cisplatin
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Culine et al. 2003 (GEFCAPI 01) | Randomized Phase II (E) | Cisplatin & Gemcitabine | Not reported |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Irinotecan (Camptosar) 150 mg/m2 IV once on day 1
21-day cycles
References
- GEFCAPI 01: Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003 Sep 15;21(18):3479-82. link to original article contains verified protocol PubMed
Docetaxel & Gemcitabine
back to top |
Regimen
Study | Evidence |
---|---|
Pouessel et al. 2004 | Phase II |
Chemotherapy
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 8
- Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 minutes once per day on days 1 & 8
Supportive medications
- Corticosteroids PO the day before, the day of, and day after Docetaxel (Taxotere)
21-day cycle for up to 6 cycles
References
- Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, Cupissol D, Pinguet F. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer. 2004 Mar 15;100(6):1257-61. link to original article contains verified protocol PubMed
Erlotinib & Bevacizumab
back to top |
Regimen
Study | Evidence |
---|---|
Hainsworth et al. 2007a | Phase II |
Chemotherapy
- Erlotinib (Tarceva) 150 mg PO on days 1 to 28, 1 hour before or 2 hours after meals
- Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
- Infusion time is 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later
28-day cycles
References
- Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA; Minnie Pearl Cancer Research Network. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007 May 1;25(13):1747-52. link to original article contains verified protocol PubMed
GCP
back to top |
GCP: Gemcitabine, Carboplatin, Paclitaxel
Regimen
Study | Evidence |
---|---|
Greco et al. 2002 | Phase II |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
- Carboplatin (Paraplatin) AUC 5 IV over 20 to 30 minutes once on day 1
- Paclitaxel (Taxol) 200 mg/m2 IV over 60 minutes once on day 1
Supportive medications
- Corticosteroids IV 30 minutes prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 300 mg IV 30 minutes prior to Paclitaxel (Taxol)
21-day cycles
References
- Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002 Mar 15;20(6):1651-6. link to original article contains verified protocol PubMed
Gemcitabine & Irinotecan
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Hainsworth et al. 2010 | Phase III (E) | PCE | Seems not superior |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
- Irinotecan (Camptosar) 100 mg/m2 IV once per day on days 1 & 8
21-day cycle for up to 6 cycles
References
- Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM, Cescon T, Bury MJ, Greco FA. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010 Jan-Feb;16(1):70-5. link to original article PubMed
PCE
back to top |
PCE: Paclitaxel, Carboplatin, Etoposide
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Greco et al. 2000a | Phase II | ||
Hainsworth et al. 2010 | Phase III (E) | Gemcitabine & Irinotecan | Seems not superior |
Chemotherapy
- Paclitaxel (Taxol) 200 mg/m2 IV over 60 minutes once on day 1
- Carboplatin (Paraplatin) AUC 6 IV over 20 to 30 minutes once on day 1
- Etoposide (Vepesid) as follows:
- Days 1, 3, 5, 7, 9: 50 mg PO once per day
- Days 2, 4, 6, 8, 10: 100 mg PO once per day
Supportive medications
- Dexamethasone (Decadron) 20 mg PO 12 hours and 4 hours prior to Paclitaxel (Taxol)
- Dexamethasone (Decadron) 20 mg IV 30 minutes prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 300 mg IV 30 minutes prior to Paclitaxel (Taxol)
21-day cycle for 4 to 8 cycles
References
- Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD. Carcinoma of unknown primary site. Cancer. 2000 Dec 15;89(12):2655-60. link to original article contains verified protocol PubMed
- Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM, Cescon T, Bury MJ, Greco FA. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010 Jan-Feb;16(1):70-5. link to original article PubMed